You take your HIV medications every day. Your viral load is undetectable. Your cholesterol numbers look fine. So heart disease is probably not something you worry about.
But a major new study says you might want to start paying attention.
The research, called REPRIEVE, followed nearly 8,000 people with HIV across 12 countries. It found that a common cholesterol-lowering drug called pitavastatin (brand name Livalo) cut the risk of heart attacks, strokes, and other serious heart events by 36 percent.
The surprising part: most of the people in the study had normal or only slightly high cholesterol.
Why HIV and heart disease are linked
People with HIV now live long, healthy lives thanks to antiretroviral therapy (ART). But they face a hidden risk. Their rate of heart disease is about 50 to 100 percent higher than people without HIV.
Doctors have known this for years. What they did not know was how to prevent it. Standard cholesterol guidelines often do not flag people with HIV as high risk. Their LDL (the "bad" cholesterol) may look acceptable. So statins, the drugs that lower cholesterol, are often not prescribed.
This left a gap. A big one.
What the old thinking missed
The old approach was simple. If your LDL cholesterol was below a certain number, your heart risk was low. No need for a statin.
But HIV changes the body in ways that cholesterol tests do not fully capture. Chronic inflammation, even at low levels, can damage blood vessels over time. The immune system stays on alert, and that constant low-grade fire may be what drives heart attacks.
Here is the twist. The REPRIEVE trial showed that lowering LDL with pitavastatin still worked. Even in people whose cholesterol was not considered high enough to treat.
How pitavastatin works in the body
Think of LDL cholesterol as tiny delivery trucks carrying fat through your bloodstream. When there are too many trucks, they can crash into blood vessel walls and cause traffic jams. Over time, those jams become blockages that lead to heart attacks or strokes.
Pitavastatin works like a traffic controller. It tells your liver to make fewer delivery trucks. Fewer trucks means less traffic. Less traffic means fewer crashes.
In this study, people taking pitavastatin saw their LDL drop by about 30 percent. That is roughly a 30-point reduction on your cholesterol lab report.
The study at a glance
The REPRIEVE trial enrolled 7,769 adults with HIV between ages 40 and 75. All were on stable ART. None had a history of heart disease. Their average LDL was 108 mg/dL, which is considered borderline or mildly elevated.
Half received 4 mg of pitavastatin daily. Half received a placebo (a sugar pill). They were followed for about five and a half years.
The headline finding is a 36 percent reduction in major heart events. But what does that look like in real life?
For every 100 people in the placebo group, about 5 had a heart attack, stroke, or needed a heart procedure over five years. In the pitavastatin group, that number dropped to about 3.
That may sound small. But across millions of people with HIV worldwide, those numbers add up to thousands of prevented heart attacks.
The researchers also looked at what drove the benefit. They found that 68 percent of the risk reduction came from lowering LDL. The rest likely came from other effects of the drug, such as reducing inflammation.
But there is a catch
The study was funded in part by the drug company that makes pitavastatin. That is common in large trials, but it is worth noting.
Also, the 68 percent figure for LDL mediation came with a wide margin of error. That means scientists are not entirely sure how much of the benefit comes from cholesterol lowering versus other effects.
If you have HIV and are over 40, this study is relevant to you. Even if your cholesterol looks fine, your heart risk may be higher than you think.
Pitavastatin is already approved by the FDA. It is available as a generic in many countries. It has fewer drug interactions with HIV medications than some other statins, which is a major advantage.
The study authors recommend that doctors consider pitavastatin for primary prevention of heart disease in people with HIV. That means taking it before you have a heart attack, not after.
Talk to your HIV doctor about your heart risk. Ask whether a statin makes sense for you. This is a conversation worth having at your next visit.
What the study does not tell us
This was one trial. It needs to be repeated in other populations. The results may not apply to everyone, especially people under 40 or those with very different health profiles.
The study also did not test other statins. It is possible that other drugs in the same class work just as well. But pitavastatin was chosen because it has fewer interactions with HIV meds.
What happens next
The REPRIEVE team plans to follow participants for longer. They want to see if the benefits hold up over a decade or more.
Other researchers are already looking at whether lower LDL targets should be set for people with HIV. Guidelines may change in the next few years.
For now, the message is clear. Heart disease is a real threat for people with HIV. And a simple, affordable pill may be part of the answer.
